-
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
10 May 2024 12:00 GMT
… subset analysis from the ZETA-1 trial was presented … a subpopulation analysis of ZETA-1 data in NPDR will … the research takeaways from the ZETA-1 trial, the efficacy …
$
53,948
Ocuphire Pharma, Inc.
Condensed Statements of Comprehensive …
-
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
06 May 2024 12:00 GMT
… clinical data from its ZETA-1 trial evaluating APX3330 … Angeles, California.
Presentation Highlights:
ZETA-1 was a Phase 2 … registration endpoint for the planned ZETA-2 Phase 2… threatening complications.” About Ocuphire Pharma Ocuphire is a clinical-stage …
-
Oliver Hudson Details ‘Debilitating’ Withdrawals From Anxiety Medication
03 May 2024 03:37 GMT
… to wean himself off anxiety medication.
Speaking to author and … to go back on medication because I just had … his withdrawal experiences from anxiety medication and antidepressants. In February … medication for five and a half years.
Demi Lovato, Catherine Zeta …
-
Network and Experimental Pharmacology on Mechanism of Yixintai Regulates the TMAO/PKC/NF-κB Signaling Pathway in Treating Heart Failure
29 Apr 2024 13:13 GMT
… lighter than in other medication groups. The mitochondria in … than that in other medication groups (Figure 10).
… on HF.
Online pharmacology has combined pharmacology with traditional medicine … repeat-containing 2; ZAP70, zeta-associated protein 70; UPLC- …
-
ZETA Acquires Majority Stake in Inosim
10 Apr 2024 08:50 GMT
… in various industries, including chemical, pharmaceutical, life sciences, and biotech. Among … Bayer, Roche, BASF and Sanofi.
ZETA said that it has already … Andreas Marchler, managing director of ZETA.
Peter Balling, CEO of Inosim …
-
Daniel Su, MD: Value of Oral APX3330 for Diabetic Retinopathy Progression
08 May 2024 16:23 GMT
… Describing the posthoc analysis of ZETA-1
5:17 Key findings … analysis of the phase 2 ZETA-1 trial, data showed a … threatening complications down the line.”
ZETA-1 was a multi-center … Given its oral delivery, Ocuphire Pharma indicated the importance of measuring …
-
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
08 Mar 2024 13:00 GMT
… safety results from the ZETA-1 Phase 2 trial … ™ for the treatment of pharmacologically-induced mydriasis. In 2023, … for the treatment of pharmacologically induced mydriasis. The balance …
$
48,992
Ocuphire Pharma, Inc.
Statements of Comprehensive (Loss …
-
The Road to Market Readiness: How Pharma Drives Innovation
04 Mar 2024 14:17 GMT
Thomas Maischberger (left) is the new Corporate Head of Research and Development at ZETA. | © ZETA
Starting from the tangible benefit for the customer
Whether researching new technologies or developing innovative products, ZETA’s customer-centric approach …
-
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
05 Feb 2024 13:00 GMT
… that clinical data from its ZETA-1 trial on a person … , remains an important unmet need.
ZETA-1 was a Phase 2 … Severity Scale (DRSS)
Analysis of ZETA-1 Phase 2 results using … oral APX3330 program.” About Ocuphire Pharma Ocuphire Pharma, Inc. is a clinical …
-
Zeta Surgical Reports Mixed Reality Navigation System Receives FDA Special 510(k) Clearance for Expanded Functionality
11 Jan 2024 16:00 GMT
Zeta Surgical Zeta Surgical, a surgical robotics and mixed reality company, announced today that its Zeta Cranial Navigation System has received Special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for expanded functionality through …